CONMED (NYSE:CNMD) Issues Earnings Results

CONMED (NYSE:CNMD) posted its quarterly earnings results on Wednesday. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.28, FiscalAI reports. The firm had revenue of $343.49 million during the quarter, compared to the consensus estimate of $337.60 million. CONMED had a return on equity of 13.84% and a net margin of 4.00%.The firm’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.15 earnings per share. CONMED updated its FY 2026 guidance to 4.480-4.600 EPS.

Here are the key takeaways from CONMED’s conference call:

• Second-quarter earnings exceeded expectations: Organic sales rose 6% year over year, while adjusted EPS increased 20% to $1.38, including a $0.21 benefit from tariff refunds. Excluding the refund, EPS still exceeded the high end of guidance by approximately $0.03.
• Core growth platforms continued to advance. General surgery organic sales grew 5.3%, orthopedic sales rose 6.8% globally, and Buffalo Filter direct smoke-evacuation sales exceeded the company’s long-term growth expectations; BioBrace also remained a key orthopedic contributor.
• AirSeal growth was positive but below expectations. Capital and disposable sales both grew sequentially, and the company expects improvement in the second half, but it lowered the pace of expected improvement while maintaining a long-term high-single-digit to low-double-digit growth outlook.
• Guidance became more cautious on revenue and cash flow. Full-year organic constant-currency sales growth guidance was narrowed to 5%-6% from 5%-6.5%, while free-cash-flow guidance declined to approximately $115 million from $125 million, primarily due to working capital, interest expense, and tax assumptions.
• EPS guidance was raised and the balance sheet was refinanced. Full-year adjusted EPS guidance increased to $4.48-$4.60, and CONMED refinanced debt by using a new $450 million term loan and revolver borrowings to repurchase $645.2 million of convertible notes ahead of their 2027 maturity.

CONMED Stock Up 12.3%

CNMD stock traded up $5.32 during midday trading on Thursday, hitting $48.53. 195,177 shares of the company’s stock were exchanged, compared to its average volume of 555,758. The firm has a 50 day moving average price of $36.89 and a 200-day moving average price of $38.39. CONMED has a 12-month low of $31.44 and a 12-month high of $56.63. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of 27.52, a price-to-earnings-growth ratio of 3.27 and a beta of 0.93. The company has a current ratio of 2.29, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q2 earnings beat estimates. CONMED reported adjusted earnings of $1.38 per share, well above the $1.10 consensus estimate and up from $1.15 a year earlier. Revenue reached $343.5 million, surpassing the $337.6 million consensus forecast. CONMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year EPS guidance was raised or reaffirmed above Wall Street expectations. CONMED forecast fiscal 2026 earnings of $4.48 to $4.60 per share, compared with analyst expectations near $4.37. The guidance supports the bullish reaction because it indicates management expects earnings momentum to continue. Conmed Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying sales growth was stronger than the headline figure. Although reported sales increased only 0.3% year over year, revenue grew 6.0% organically when excluding the impact of previously announced strategic exits from certain gastrointestinal product offerings. This suggests the continuing business is performing better than reported growth implies. CONMED Corp Q2 2026 Earnings

Hedge Funds Weigh In On CONMED

Several institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. increased its stake in shares of CONMED by 29.9% in the fourth quarter. Invesco Ltd. now owns 184,070 shares of the company’s stock worth $7,473,000 after buying an additional 42,395 shares during the last quarter. State of Tennessee Department of Treasury boosted its stake in CONMED by 4.3% during the 4th quarter. State of Tennessee Department of Treasury now owns 21,139 shares of the company’s stock valued at $812,000 after acquiring an additional 873 shares during the last quarter. VARCOV Co. bought a new position in CONMED during the 4th quarter valued at $1,007,000. Voloridge Investment Management LLC grew its holdings in CONMED by 92.6% during the 4th quarter. Voloridge Investment Management LLC now owns 210,193 shares of the company’s stock worth $8,534,000 after acquiring an additional 101,052 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in CONMED during the 4th quarter worth $1,517,000.

Wall Street Analysts Forecast Growth

CNMD has been the topic of several research analyst reports. Zacks Research lowered CONMED from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings restated a “sell (d)” rating on shares of CONMED in a report on Thursday, June 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research report on Monday, July 13th. Wells Fargo & Company lifted their price target on shares of CONMED from $39.00 to $46.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, BMO Capital Markets began coverage on shares of CONMED in a research note on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price objective for the company. Five equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $40.20.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.